Associate Professor, Pathology, Anatomy and Cell Biology, Jefferson Medical College-Thos Jefferson Univ
Pathology
Dr. Agnieszka K. Witkiewicz, MD
Agnieszka K. Witkiewicz works in the field of Pathology. She graduated from NYU School of Medicine. Agnieszka K. Witkiewicz is also published. She has 101 publications published. The lastest publication: "Immunological and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.'
Publications
- Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.
- Immunological and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
- Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.
- MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
- Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs.
- The history and future of targeting cyclin-dependent kinases in cancer therapy.
- The RB tumor suppressor at the intersection of proliferation and immunity: Relevance to disease immune evasion and immunotherapy.
- MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies.
- Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
- CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
- Contrast-enhanced sonography for detection of secondary lymph nodes in a melanoma tumor animal model.
- Retinoblastoma protein potentiates the innate immune response in hepatocytes: Significance to hepatocellular carcinoma.
- RB Tumor Suppressive Function in Response to Xenobiotic Hepatocarcinogens.
- dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial.
- The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.
- EZH2 and ALDH1 expression in ductal carcinoma in situ: Complex association with recurrence and progression to invasive breast cancer.
- Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer.
- Regulation of miR106b cluster through the RB pathway: Mechanism and functional targets.
- Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma.
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
- Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue.
- Intraductal Papillary Mucinous Neoplasm (IPMN) with Extra-Pancreatic Mucin: A Case Series and Review of the Literature.
- Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival.
- Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.
- Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
- Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualizing the therapeutic effects of metformin in tumor tissue.
- Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma.
- Molecular Profiling of Synchronous and Metachronous Cancers of the Pancreas Reveal Molecular Mimicry Between Samples from the Same Patient.
- RB Restricts DNA Damage-Initiated Tumorigenesis through an LXCXE-Dependent Mechanism of Transcriptional Control.
- The meaning of p16 (ink4a) expression in tumors: Functional significance, clinical associations and future developments.
- Association of RB/p16-Pathway Perturbations with DCIS Recurrence Dependence on Tumor versus Tissue Microenvironment.
- Caveolin-2-deficient mice show increased sensitivity to endotoxemia.
- Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.
- Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers.
- Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts.
- Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure.
- RB pathway and therapeutic sensitivity: New insights in breast cancer and Tamoxifen therapy.
- The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
- The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.
- PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.
- Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma.
- Detection of Merkel cell carcinoma polyomavirus in mucosal Merkel cell carcinoma.
- Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.
- Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
- CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers.
- HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
- Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic ins...
- Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence.
- Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
- Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors.
- The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.
- Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.
- Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with pro...
- pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
- The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.
- Foxp3-expressing T regulatory cells and mast cells in acute graft-versus-host disease of the skin.
- Acinar Cell Carcinoma With a Prominent Intraductal Growth Pattern: Case Report With Review of the Literature.
- Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.
- Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer.
- The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
- An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
- Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy.
- Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation.
- Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.
- Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
- Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions.
- Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.
- Expression of K homology domain containing protein (KOC) in pancreatic cytology with corresponding histology.
- Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.
- Graft-versus-Host Disease-Like Pattern in Mycophenolate Mofetil Related Colon Mucosal Injury: Role of FISH in Establishing the Diagnosis.
- Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome.
- Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature.
- Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast.
- Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
- Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells.
- RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
- Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway.
- The ''RNA-binding ome'': future implications for chemotherapeutic efficacy.
- Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma.
- Carotid body tumor (paraganglioma).
- Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases.
- Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.
- Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.
- Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
- Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS.
- Juvenile amyopathic dermatomyositis.
- Pityriasis rubra pilaris, type IV.
- Mutations in the desmoglein 4 gene underlie localized autosomal recessive hypotrichosis with monilethrix hairs and congenital scalp erosions.
- Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome.
- Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
- IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
- Renal cell carcinoma metastatic to the duodenum: treatment by classic pancreaticoduodenectomy and review of the literature.
- Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders.
- Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to horm...
- The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.
- RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.
- Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.
- Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.
Doctors Specialties
- Dermatopathology
- Pathology
Accepted Insurances
Education
-
NYU School of Medicine -
University of Massachusetts -
Wroclaw Medical University
Hospital
-
Thomas Jefferson University Hospital -
University of Texas Southwestern Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538177159 |
| Last Name Of The Provider | WITKIEWICZ |
| First Name Of The Provider | AGNIESZKA |
| View All |
Similar Doctors
|
Dr. Ravindra Sarode, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Terry L. Barrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael E. Black, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara Partridge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laszlo Karai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph S. Susa, DO |
|
|
Dr. Karen Matevosyan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter Simon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clayton L. VanDergriff, MD
This Doctor is OpenDoctor Recommended.
|